Moskop J C
Hastings Cent Rep. 1987 Apr;17(2):11-5.
In the current era of cost-containment, Congress may reconsider its support for the End-Stage Renal Disease Program. Substantial reductions in funding for this program could be made by eliminating non-beneficial, marginally beneficial, and relatively inefficient modes of treatment. These measures, however, will only postpone the inevitable day when clearly beneficial treatment must be withheld.
在当前成本控制的时代，国会可能会重新考虑其对终末期肾病项目的支持。通过消除无益处、益处不大以及效率相对较低的治疗方式，可以大幅削减该项目的资金。然而，这些措施只会推迟不可避免的一天，即必须停止明显有益的治疗。
